Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Pediatric Patients

Rohtesh S. Mehta, MDMPH,MS, Shernan G. Holtan, MD, Tao Wang, PhD, Michael T. Hemmer, MS, Stephen R. Spellman, Mukta Arora, MD, Daniel R. Couriel, MD, Amin M. Alousi, Joseph Pidala, MD PhD, Daniel J. Weisdorf, MD

Blood (2017) 130 (Supplement 1): 2053.

https://doi.org/10.1182/blood.V130.Suppl_1.2053.2053

Published: 2017

Journal Articles

Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Adults

Blood (2017) 130 (Supplement 1): 517.

https://doi.org/10.1182/blood.V130.Suppl_1.517.517

Published: 2017

Journal Articles

Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Attaphol Pawarode, MD, Steven Goldstein, MD, Daniel R. Couriel, MD, Thomas Braun, PhD, John M. Magenau, MD, Mary Mansour Riwes, DO, Brian Parkin, Vedran Radojcic, MD, David Frame, PharmD, Sung Choi, MD, James Connelly, MD, John E. Levine, MD MS, Gregory A. Yanik, MD, Pavan Reddy, MD

Blood (2015) 126 (23): 1907.

https://doi.org/10.1182/blood.V126.23.1907.1907

Published: 2015

Journal Articles

Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?

Hanna Jean Khoury, MD, Tao Wang, PhD, Mukta Arora, MD, Michael Hemmer, MS, Stephen R. Spellman, MBS, Corey S Cutler, MD MPH, Daniel R. Couriel, MD, Amin M. Alousi, MD, Joseph A. Joseph, MD

Blood (2015) 126 (23): 3132.

https://doi.org/10.1182/blood.V126.23.3132.3132

Published: 2015

Journal Articles

Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations

Sarah Nikiforow, MD PhD, Michael Hemmer, MS, Stephen R. Spellman, MBS, Amin M. Alousi, MD, Daniel R. Couriel, MD, Joseph A Pidala, MD, PhD, Mukta Arora, MD, Corey S Cutler, MD MPH, Tao Wang, PhD

Blood (2015) 126 (23): 857.

https://doi.org/10.1182/blood.V126.23.857.857

Published: 2015

Journal Articles

Prognostic Value of TGFβ at Diagnosis of Chronic GvHD

Rima M Saliba, PhD, Carrie Kitko, MD, Pavan Reddy, MD, John M. Magenau, MD, Attaphol Pawarode, Steven Goldstein, Daniel R. Couriel, MD

Blood (2014) 124 (21): 5875.

https://doi.org/10.1182/blood.V124.21.5875.5875

Published: 2014

Journal Articles

Comparison of Tacrolimus Versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia: A CIBMTR Analysis

Yoshihiro Inamoto, MD PhD, Paul J. Martin, MD, Mary E. Flowers, MD, Alvaro Urbano-Ispizua, MD, Tao Wang, PhD, Michael T. Hemmer, MS, Corey S Cutler, MD MPH, Daniel R. Couriel, MD, Amin M. Alousi, MD, Mukta Arora, MD MS, Stephen R. Spellman, MBS

Blood (2014) 124 (21): 4383.

https://doi.org/10.1182/blood.V124.21.4383.4383

Published: 2014

Journal Articles

Ex Vivo Pharmacologic Modulation in a Nutrient-Rich Medium to Accelerate Engraftment of Human Umbilical Cord Blood

Corey S Cutler, MD MPH, Daniel Shoemaker, PhD, Peter Westervelt, MD PhD, Daniel R. Couriel, MD, Sumithra Vasu, MBBS, Luis M. Isola, MD, Chatchada Karanes, MD, Laura Newell, MD, Betsy Rezner, BS, Lisa Guerrettaz, PhD, David Robbins, BS, Amanda Medcalf, BS, MT(ASCP), Scott Wolchko, MS, John Ferraro, MBA, Pratik S. Multani, MD MS

Blood (2014) 124 (21): 3807.

https://doi.org/10.1182/blood.V124.21.3807.3807

Published: 2014

Journal Articles

The CIBMTR Chronic GVHD Risk Group Predicts Major Outcomes In An Independent Validation Cohort

Blood (2013) 122 (21): 706.

https://doi.org/10.1182/blood.V122.21.706.706

Published: 2013

Journal Articles

Application Of BOS 0-Potential Criteria As a Predictor For Bronchiolitis Obliterans Syndrome In Allogeneic Stem Cell Transplant Patients

Sameem Abedin, MD, Gregory A. Yanik, MD, John M. Magenau, MD, Steven C. Goldstein, MD, Attaphol Pawarode, MD, John E. Levine, M.D., M.S., Carrie L. Kitko, MD, Daniel R. Couriel, MD

Blood (2013) 122 (21): 2060.

https://doi.org/10.1182/blood.V122.21.2060.2060

Published: 2013

Journal Articles

Pneumocystis Jirovecii Pneumonia In Recipients Of Autologous Hematopoietic Stem Cell Transplantation: A 10-Year Cohort Study

Kadee J Raser, M.S., PA-C, Gregory A. Yanik, MD, John M. Magenau, M.D., Steven C. Goldstein, MD, Attaphol Pawarode, Carrie Kitko, M.D., John E. Levine, M.D., M.S., David Hanauer, M.S., M.D., Daniel R. Couriel, MD

Blood (2013) 122 (21): 3372.

https://doi.org/10.1182/blood.V122.21.3372.3372

Published: 2013

Journal Articles

Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research

Sally Arai, MD, Mukta Arora, MD, MS, Tao Wang, PhD, Wensheng He, PhD, MS, Daniel R. Couriel, MD, Alvaro Urbano-Ispizua, MD, Corey S. Cutler, MD, Stephen Spellman, MBS, Steven Z. Pavletic, MD

Blood (2013) 122 (21): 3309.

https://doi.org/10.1182/blood.V122.21.3309.3309

Published: 2013

Journal Articles

A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis

Jesus G. Berdeja, MD, Daniel R. Couriel, MD, Patrick Murphy, MD, Ralph V. Boccia, MD, Victor Priego, MD, John D. Hainsworth, MD, Inés M. Macias-Pérez, PhD, Ian W. Flinn, MD, PhD

Blood (2011) 118 (21): 2943.

https://doi.org/10.1182/blood.V118.21.2943.2943

Published: 2011

Journal Articles

A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS).

Guillermo Garcia-Manero, MD, Daniel R. Couriel, MD, Francesco Paolo Tambaro, MD, PhD, Nashat Gabrail, Ahmed Nadeem, MD, Tapan Kadia, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Stefan Faderl, MD, Willie Newsome, RN, Hui Yang, MD, PhD, Kevin Chen, Karen Stein, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 119.

https://doi.org/10.1182/blood.V114.22.119.119

Published: 2009

Journal Articles

High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients.

Richard W Joseph, Jr., MD, Krishna V. Komanduri, M.D., R. M Saliba, MD, Amin Alousi, MD, S. Giralt, Gabriela Rondon, Joyce Neumann, Cindy Trevino, APN, Daniel R. Couriel, MD, Richard Champlin, U. Popat

Blood (2008) 112 (11): 2138.

https://doi.org/10.1182/blood.V112.11.2138.2138

Published: 2008

Journal Articles

Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma.

Muzaffar H. Qazilbash, MD, Rima M. Saliba, PhD, Gaurav Parikh, MD, Chitra Hosing, MD, Floralyn Mendoza, MD, Suhail P. Qureshi, MD, Donna M. Weber, MD, Michael Wang, MD, Thuy Flosser, Daniel R. Couriel, MD, Partow Kebriaei, MD, Uday Popat, MD, Amin Alousi, MD, Marcos de Lima, MD, Richard E. Champlin, MD, Sergio Giralt, MD

Blood (2007) 110 (11): 942.

https://doi.org/10.1182/blood.V110.11.942.942

Published: 2007

Journal Articles

Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).

Jason R. Westin, MD, Rima M. Saliba, PHD, Marcos de Lima, MD, Amin Alousi, MD, Chitra Hosing, MD, Muzaffar H. Qazilbash, MD, Issa F. Khouri, MD, Elizabeth J. Shpall, MD, Richard Champlin, MD, Daniel R. Couriel, MD

Blood (2007) 110 (11): 5015.

https://doi.org/10.1182/blood.V110.11.5015.5015

Published: 2007

Journal Articles

Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin’s Lymphoma.

Rima M. Saliba, PhD, Issa F. Khouri, MD, Marcos de Lima, MD, Chitra Hosing, MD, Grace Okoroji, MS, Sandra Acholonou, MS, Farzaneh Maadani, MS, Jorge De Jesus, RN, Yvonne Hsu, PA, Richard E. Champlin, MD, Daniel R. Couriel, MD

Blood (2006) 108 (11): 5316.

https://doi.org/10.1182/blood.V108.11.5316.5316

Published: 2006

Journal Articles

Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Muzaffar H. Qazilbash, MD, Rima M. Saliba, PhD, Marilyn S. Davis, Floralyn L. Mendoza, Chitra Hosing, MD, Daniel R. Couriel, MD, Marcos De Lima, MD, Partow Kebriaei, MD, Donna M. Weber, MD, Michael Wang, MD, Amin M. Alousi, MD, Steven G. Matthes, Roy B. Jones, MD, PhD, Richard E. Champlin, MD, Sergio A. Giralt, MD

Blood (2006) 108 (11): 3090.

https://doi.org/10.1182/blood.V108.11.3090.3090

Published: 2006

Journal Articles

Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.

Bilal Ahmed, MD, Rima M. Saliba, PhD, Noman Ashraf, MD, Floralyn Mendoza, Chitra Hosing, MD, Thuy Flosser, Donna M. Weber, MD, Michael Wang, MD, Daniel R. Couriel, MD, Uday Popat, MD, Partow Kebriaei, MD, Amin M. Alousi, MD, Richard E. Champlin, MD, Sergio A. Giralt, MD, Muzaffar H. Qazilbash, MD

Blood (2006) 108 (11): 3101.

https://doi.org/10.1182/blood.V108.11.3101.3101

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Pediatric Patients

Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Adults

Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?

Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations

Prognostic Value of TGFβ at Diagnosis of Chronic GvHD

Comparison of Tacrolimus Versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia: A CIBMTR Analysis

Ex Vivo Pharmacologic Modulation in a Nutrient-Rich Medium to Accelerate Engraftment of Human Umbilical Cord Blood

The CIBMTR Chronic GVHD Risk Group Predicts Major Outcomes In An Independent Validation Cohort

Application Of BOS 0-Potential Criteria As a Predictor For Bronchiolitis Obliterans Syndrome In Allogeneic Stem Cell Transplant Patients

Pneumocystis Jirovecii Pneumonia In Recipients Of Autologous Hematopoietic Stem Cell Transplantation: A 10-Year Cohort Study

Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research

A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis

A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS).

High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients.

Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma.

Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).

Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin’s Lymphoma.

Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only